Genomes and Genes
Role of Splicing Factors in Breast Cancer
Principal Investigator: OLGA ANCZUKOW-CAMARDA
Abstract: DESCRIPTION (provided by applicant): Cancer cells often display aberrant profiles of alternative splicing, leading to the production of protein isoforms that can increase cell proliferation, migration, and apoptotic resistance. My long-term goal is to establish an independent research lab, where I will elucidate molecular mechanisms by which alternative splicing misregulation plays a role in cancer by altering the expression of various oncogenes and tumor-suppressor genes. Importantly, these findings will translate into the development of novel therapeutic strategies. The K99/R00 career award will help in achieving this goal by advancing my training in: antisense oligonucleotide technologies under the guidance of my primary mentor Dr. Adrian Krainer;next-generation sequencing under the co-mentorship of Dr. Michael Schatz;and metastatic breast cancer models under the co-mentorship of Dr. Mikala Egeblad. This training will complement my previous expertise in breast cancer research and RNA splicing mechanisms. The very stimulating scientific environment at Cold Spring Harbor Laboratory will not only provide me with the expertise and facilities necessary for the completion of the mentored phase of this project, but will also prepare me to transition smoothly into an independent faculty position. During the K99 mentored phase, I will define the role of splicing factors and splicing misregulation in breast cancer. In the subsequent R00 independent phase, I will indentify oncogenic splicing events that could constitute therapeutic targets to pursue during my future independent research. We have previously demonstrated that overexpression of the splicing factor SRSF1 can transform human mammary epithelial cells in vitro and in vivo. We have also shown that SRFS1 levels are directly regulated by the MYC oncoprotein. However, additional splicing factors are also overexpressed in human breast tumors, suggesting that they may also play a role in breast cancer. In Aim 1, during the K99 phase, I will determine the role of specific splicing factors in breast cancer using relevant cell and animal models that mimic the biological context in which the tumors arise. This includes: (i) identifying changes in alternative splicing events underlying splicing-factor- mediated transformation by next-generation RNA-sequencing in 3-D cultures of human mammary epithelial cells;and (ii) defining the metastatic potential of these oncogenic splicing factors using in vivo mouse models. In Aim 2, during the K99 phase, I will determine the role of MYC in the regulation of alternative splicing in breast cancer, by identifying changes in both splicing-factor expression and in alternative splicing profiles by next-generation RNA-sequencing in a MYC-inducible cell culture system. In Aim 3, during the R00 phase, I will determine the role of splicing factors in acquisition of resistance to tyrosine kinase inhibitors in breast cancer, by identifying changes in splicing-factor levels and i alternative splicing events. Finally, starting in the K99 phase and leading into the R00 phase, I will determine the therapeutic potential of using antisense oligonucleotides to modulate specific oncogenic alternative splicing events identified in Aims 1-3. The proposed research will identify not only splicing factors involved in breast cancer but also their regulators and specific targets. This plan will establish the basis for my independent research program, in which I plan to contribute to the development of new cancer therapies based on modulating the expression and activity of splicing factors or their targets.
Funding Period: 2013-09-01 - 2015-08-31
more information: NIH RePORT
- Mechanisms of Esophageal CarcinogenesisAnil K Rustgi; Fiscal Year: 2013..abstract_text> ..
- Molecular Pathogenesis of Basal-like Breast CancerRichard J Baer; Fiscal Year: 2013..e., metastasis, and develop strategies for therapy. ..
- South Carolina Cancer Disparities Community Network -- IIJames R Hebert; Fiscal Year: 2013....
- ROLES AND REGULATION OF P53Carol Prives; Fiscal Year: 2013..The projects are even more interdependent and interactive than before and as a result much of the proposed research cannot be done effectively without the support of this program. ..
- Specialized Program of Research ExcellenceJennifer Rubin Grandis; Fiscal Year: 2013..abstract_text> ..
- Signaling and Progression in Prostate CancerDan Theodorescu; Fiscal Year: 2013..The long-term objective is to translate our understanding of prostate cancer progression mechanisms into the identification of new drug targets and pre-clinical models that recapitulate key aspects of the human disease. ..
- University of Maryland Greenebaum Cancer Center Support GrantKevin J Cullen; Fiscal Year: 2013..Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research. ..
- SPORE in Soft Tissue SarcomaSamuel Singer; Fiscal Year: 2013..abstract_text> ..
- Proteolytic matriptase-prostasin axis in breast cancerKarin List; Fiscal Year: 2013..The combination of state-of-the art mouse genetics with 2D and 3D cell culture based assays encompasses an innovative strategy for studying human cancerous disease, and may offer new avenues for diagnosis and therapy of breast cancer. ..
- Role of 11q23 Chromosome Abnormalities in the Causation of Acute LeukemiaCarlo M Croce; Fiscal Year: 2013..abstract_text> ..
- INTEGRATIVE PATHOPHYSIOLOGY OF SOLID TUMORSRakesh K Jain; Fiscal Year: 2013..abstract_text> ..
- Interrogating Epigenetic Changes in Cancer GenomesTim H M Huang; Fiscal Year: 2013..abstract_text> ..
- The Biology of Prostate Cancer Skeletal MetastasesEVAN TODD KELLER; Fiscal Year: 2013..This combination of investigators, projects and cores result in a highly synergistic Program that will continue to provide cutting-edge research on PCa bone metastases. ..
- Mechanistic Pharmacology of Anti-Mitotics and Apoptosis RegulationTimothy J Mitchison; Fiscal Year: 2013..In aim 4 we will pursue several approaches towards translating mechanistic understanding from aims 1-3 into improved patient care. ..
- Model-based predictions of responses RTK Pathway therapiesJoe W Gray; Fiscal Year: 2013..abstract_text> ..
- Exploiting synthetic-lethal interactions to target triple-negative breast cancersDai Horiuchi; Fiscal Year: 2013..If successful, the proposed research will not only expand our knowledge on MYC biology but will also provide novel therapeutic concepts to be tested again patients with TN tumors. ..
- CENTER FOR BIOMEDICAL RESEARCHTimothy Turner; Fiscal Year: 2013..abstract_text> ..